Mini-Oral Session

[MO27] Mini-Oral Session 27　Head and Neck Cancer 2（Clinical Practice）
【E】

Fri. Feb 18, 2022 2:05 PM - 2:55 PM Room 9 (Swan, 1F, Kyoto International Conference Center)

Chair：Yoshinori Imamura（Department of Medical Oncology and Hematology, Kobe University Hospital），Susumu Okano（Department of Head and Neck Medical Oncology, National Cancer Center Hospital East）

+Add all to schedule

[MO27-1] Weekly versus Three-Weekly Cisplatin Administration in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

^○Ramon Jr B. Larrazabal¹, Harold Henrison C. Chiu², Irisyl O. Real¹ (1.Division of Medical Oncology, Department of Medicine, Philippine General Hospital, 2.Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Philippine General Hospital)

[MO27-2] Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer

^○Ari Nishimura¹, Yokota Tomoya¹, Hamauchi Satoshi¹, Onozawa Yusuke¹, Shirasu Hiromichi¹, Notsu Akifumi², Sato Fuyuki³, Kawakami Takeshi¹, Ogawa Hirofumi⁴, Onoe Tsuyoshi⁴, Mukaigawa Takashi⁵ (1.Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 2.Department of Biostatistics, Clinical Research Center, Shizuoka Cancer Center, 3.Division of Pathology, Shizuoka Cancer Center, 4.Division of Radiation Oncology, Shizuoka Cancer Center, 5.Division of Head and Neck Surgery, Shizuoka Cancer Center)

[MO27-3] The mGPS is a potential predictor for early recurrences in patients with HNSCC who underwent chemoradiotherapy

^○Shohei Udagawa¹, Naoki Fukuda¹, Yasuyoshi Sato¹, Yu Fujiwara^1,2, Xiaofei Wang¹, Naomi Hayashi¹, Kenji Nakano¹, Ryosuke Ohki¹, Tetsuya Urasaki¹, Hirotaka Suto¹, Akihiro Ohmoto¹, Makiko Ono¹, Junichi Tomomatsu¹, Takashi Toshiyasu³, Hiroki Mitani⁴, Shunji Takahashi¹ (1.Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 2.Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, USA., 3.Department of Radiation Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 4.Department of Head and Neck Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan)

[MO27-4] Chemoembolization with followed radiation therapy in patients with locally advanced nasopharyngeal carcinoma

^○Alexander S Mitrofanov¹, Zamira A.-G. Radzhabova¹, Maxim A. Kotov¹, Said D. Radzhabov², Michail M. Girshovich¹, Olga I. Ponomareva¹ (1.NMRC of Oncology named after N.N.Petrov of MoH of Russia, 2.Polenov Neurosurgical Institute)

[MO27-5] Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma: a retrospective study

^○Hiroyuki Kodama¹, Shigenori Kadowaki¹, Akinobu Nakata¹, Ryosuke Kumanishi¹, Taiko Nakazawa¹, Takatsugu Ogata¹, Yuki Matsubara¹, Kazunori Honda¹, Toshiki Masuishi¹, Yukiya Narita¹, Hiroya Taniguchi¹, Masashi Ando¹, Nobuhiro Hanai², Kei Muro¹ (1.Department of Clinical Oncology, Aichi Cancer Center Hospital, 2.Department of Head and Neck Surgery, Aichi Cancer Center Hospital)

[MO27-6] When should we start sorafenib or lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma?

^○Yasuhiro Ito^1,2, Onoda Naoyoshi², Akira Miyauchi² (1.Department of Clinical Trial, Kuma Hospital, 2.Department of Surgery, Kuma Hospital)